Waldenstrom macroglobulinemia (WM) is a rare cancer of B lymphocytes associated with lymphoplasmacytic bone marrow infiltration and the presence of serum monoclonal immunoglobulin M (IgM) (LLS, 2021). Often considered a disease occurring in older adults, this malignancy accounts for between 1% and 2% of non-Hodgkin lymphomas (Dimopoulos & Kastritis, 2019; ACS, 2018). Whereas patients with low- and intermediate-risk disease have 5-year survival rates of 87% and 68%, respectively, those with high-risk disease have a 5-year survival rate of only 36% (ACS, 2018). Waldenstrom macroglobulinemia is a disease that requires keeping up to date on the knowledge of risk stratification systems, efficacy and safety data for novel therapeutic approaches, and surveillance and management strategies for adverse events associated with novel treatments (i3 Health, 2021). In this activity, Morie Gertz, MD, MACP, will update providers on the latest evidence-based treatment and management plans for patients with WM.